澳大利亚政府向Visanne提供补贴,使内分泌硬化病患者更负担得起。 Australian government to subsidize Visanne, making it more affordable for endometriosis sufferers.

澳大利亚政府将30年来首次补贴Visanne(dienogest), 使100多万患内分泌硬化症的澳大利亚人更能负担得起。 The Australian government will subsidize Visanne (dienogest) for the first time in 30 years, making it more affordable for the over one million Australians suffering from endometriosis. 每天的药片通过抑制异常组织生长,有助于减少严重时期疼痛和大量出血等症状。 The daily tablet helps reduce symptoms like severe period pain and heavy bleeding by suppressing abnormal tissue growth. 以前每年花费约750美元,补贴是1.07亿美元的内分泌支持投资的一部分。 Previously costing around $750 a year, the subsidy is part of a $107 million investment in endometriosis support.